{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:42:45Z","timestamp":1794008565138,"version":"4.8.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) of the previously reported phase 1b trial (NCT02157792) is based on the recommended phase 2 dose of the combination of the ataxia-telangiectasia and Rad3-related (ATR) inhibitor berzosertib and cisplatin observed in patients with advanced solid tumors, including TNBC. Forty-seven patients aged \u226518 years with advanced TNBC received cisplatin (75\u2009mg\/m<jats:sup>2<\/jats:sup>; day 1) and berzosertib (140\u2009mg\/m<jats:sup>2<\/jats:sup>; days 2 and 9), in 21-day cycles. Berzosertib was well tolerated, with a similar toxicity profile to that reported previously for this combination. The overall response rate (90% confidence interval) was 23.4% (13.7, 35.8). No relevant associations were observed between response and gene alterations. Further studies combining ATR inhibitors with platinum compounds may be warranted in highly selected patient populations.<\/jats:p>","DOI":"10.1038\/s41523-022-00406-0","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T10:20:54Z","timestamp":1649326854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer"],"prefix":"10.1038","volume":"8","author":[{"given":"Melinda L.","family":"Telli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-4095","authenticated-orcid":false,"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-5609","authenticated-orcid":false,"given":"Simon R.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik Tobias","family":"Arkenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-2901","authenticated-orcid":false,"given":"Andrew","family":"Tutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tufia C.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ferrer-Playan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Goddemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grombacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fleuranceau-Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Diaz-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0107-1444","authenticated-orcid":false,"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"406_CR1","first-page":"175883592095835","volume":"12","author":"KJ Lee","year":"2020","unstructured":"Lee, K. J. et al. Exploiting DNA repair defects in triple negative breast cancer to improve cell killing. Ther. Adv. Med. Oncol. 12, 1758835920958354 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"406_CR2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader, N., Cronin, K. A., Kurian, A. W. & Andridge, R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol. Biomark. Prev. 27, 619\u2013626 (2018).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"406_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0959-8049(09)70013-9","volume":"45","author":"SJ Dawson","year":"2009","unstructured":"Dawson, S. J., Provenzano, E. & Caldas, C. Triple negative breast cancers: clinical and prognostic implications. Eur. J. Cancer 45, 27\u201340 (2009).","journal-title":"Eur. J. Cancer"},{"key":"406_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7\u201330 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"406_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1634\/theoncologist.2012-0397","volume":"18","author":"A Prat","year":"2013","unstructured":"Prat, A. et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18, 123\u2013133 (2013).","journal-title":"Oncologist"},{"key":"406_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.soc.2017.08.005","volume":"27","author":"SM Fragomeni","year":"2018","unstructured":"Fragomeni, S. M., Sciallis, A. & Jeruss, J. S. Molecular subtypes and local-regional control of breast cancer. Surg. Oncol. Clin. N. Am. 27, 95\u2013120 (2018).","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"406_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt, A. et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat. Med. 24, 628\u2013637 (2018).","journal-title":"Nat. Med."},{"key":"406_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"WM Sikov","year":"2015","unstructured":"Sikov, W. M. et al. Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J. Clin. Oncol. 33, 13\u201321 (2015).","journal-title":"J. Clin. Oncol."},{"key":"406_CR9","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","volume":"29","author":"S Loibl","year":"2018","unstructured":"Loibl, S. et al. Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann. Oncol. 29, 2341\u20132347 (2018).","journal-title":"Ann. Oncol."},{"key":"406_CR10","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso, F. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol. 31, 1623\u20131649 (2020).","journal-title":"Ann. Oncol."},{"key":"406_CR11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"New Engl. J. Med."},{"key":"406_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 44\u201359 (2020).","journal-title":"Lancet Oncol."},{"key":"406_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia, A. et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. New Engl. J. Med. 380, 741\u2013751 (2019).","journal-title":"New Engl. J. Med."},{"key":"406_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.18632\/oncoscience.474","volume":"6","author":"M Beniey","year":"2019","unstructured":"Beniey, M., Haque, T. & Hassan, S. Translating the role of PARP inhibitors in triple-negative breast cancer. Oncoscience 6, 287\u2013288 (2019).","journal-title":"Oncoscience"},{"key":"406_CR15","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.20.02151","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung, N. M. et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J. Clin. Oncol. 38, 4274\u20134282 (2020).","journal-title":"J. Clin. Oncol."},{"key":"406_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol. Cell 66, 801\u2013817 (2017).","journal-title":"Mol. Cell"},{"key":"406_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/bjc.2011.243","volume":"105","author":"A Peasland","year":"2011","unstructured":"Peasland, A. et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br. J. Cancer 105, 372\u2013381 (2011).","journal-title":"Br. J. Cancer"},{"key":"406_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper, P. M. et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 7, 428\u2013430 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"406_CR19","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1038\/onc.2010.624","volume":"30","author":"N Sangster-Guity","year":"2011","unstructured":"Sangster-Guity, N., Conrad, B. H., Papadopoulos, N. & Bunz, F. ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene 30, 2526\u20132533 (2011).","journal-title":"Oncogene"},{"key":"406_CR20","doi-asserted-by":"crossref","unstructured":"Middleton, F. K., Pollard, J. R. & Curtin, N. J. The impact of p53 dysfunction in ATR inhibitor cytotoxicity and chemo- and radiosensitisation. Cancers (Basel) 10, 275 (2018).","DOI":"10.3390\/cancers10080275"},{"key":"406_CR21","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey, L. A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492\u20132502 (2006).","journal-title":"JAMA"},{"key":"406_CR22","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.breast.2013.07.005","volume":"22","author":"P Bertheau","year":"2013","unstructured":"Bertheau, P. et al. p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast 22, S27\u2013S29 (2013).","journal-title":"Breast"},{"key":"406_CR23","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.18632\/oncotarget.2158","volume":"5","author":"AB Hall","year":"2014","unstructured":"Hall, A. B. et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget 5, 5674\u20135685 (2014).","journal-title":"Oncotarget"},{"key":"406_CR24","doi-asserted-by":"crossref","unstructured":"Middleton, M. R. et al. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours. Br. J. Cancer 125, 510\u2013519 (2021).","DOI":"10.1038\/s41416-021-01405-x"},{"key":"406_CR25","doi-asserted-by":"crossref","unstructured":"Shapiro, G. I. et al. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. Br. J. Cancer 125, 520\u2013527 (2021).","DOI":"10.1038\/s41416-021-01406-w"},{"key":"406_CR26","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap, T. A. et al. Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J. Clin. Oncol. 38, 3195\u20133204 (2020).","journal-title":"J. Clin. Oncol."},{"key":"406_CR27","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","volume":"21","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos, P. A. et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 21, 957\u2013968 (2020).","journal-title":"Lancet Oncol."},{"key":"406_CR28","doi-asserted-by":"crossref","unstructured":"Terranova, N., Jansen, M., Falk, M. & Hendriks, B. S. Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types. Cancer Chemother. Pharmacol. 87, 185\u2013196 (2020).","DOI":"10.1007\/s00280-020-04184-z"},{"key":"406_CR29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","volume":"39","author":"A Thomas","year":"2021","unstructured":"Thomas, A. et al. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell 39, 566\u2013579.e567 (2021).","journal-title":"Cancer Cell"},{"key":"406_CR30","unstructured":"FDA. FoundationFocus CDxBRCA LOH - P160018\/S001, https:\/\/www.fda.gov\/medical-devices\/recently-approved-devices\/foundationfocus-cdxbrca-loh-p160018s001 (2018)."},{"key":"406_CR31","unstructured":"Foundation Medicine, I. FoundationOne\u00aeCDx Technical Information, https:\/\/assets.ctfassets.net\/w98cd481qyp0\/41rJj28gFwtxCwHQxopaEb\/2725881bbc67d6f323ab893851344c4a\/FoundationOne_CDx_Label_Technical_Info.pdf."},{"key":"406_CR32","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","volume":"33","author":"SJ Isakoff","year":"2015","unstructured":"Isakoff, S. J. et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J. Clin. Oncol. 33, 1902\u20131909 (2015).","journal-title":"J. Clin. Oncol."},{"key":"406_CR33","doi-asserted-by":"crossref","unstructured":"Pal, S. K. et al. Effect of cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 7, 1536\u20131543 (2021).","DOI":"10.1001\/jamaoncol.2021.3441"},{"key":"406_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nsmb.2076","volume":"18","author":"LI Toledo","year":"2011","unstructured":"Toledo, L. I. et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 18, 721\u2013727 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"406_CR35","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/nsmb.2189","volume":"18","author":"M Murga","year":"2011","unstructured":"Murga, M. et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat. Struct. Mol. Biol. 18, 1331\u20131335 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"406_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1101\/gad.345454.120","volume":"35","author":"XA Su","year":"2021","unstructured":"Su, X. A. et al. RAD21 is a driver of chromosome 8 gain in Ewing sarcoma to mitigate replication stress. Genes Dev. 35, 556\u2013572 (2021).","journal-title":"Genes Dev."},{"key":"406_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13837","volume":"7","author":"CT Williamson","year":"2016","unstructured":"Williamson, C. T. et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat. Commun. 7, 13837 (2016).","journal-title":"Nat. Commun."},{"key":"406_CR38","doi-asserted-by":"crossref","unstructured":"Yap, T. A. et al. First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 11, 80\u201391 (2020).","DOI":"10.1158\/2159-8290.CD-20-0868"},{"key":"406_CR39","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","volume":"107","author":"V Abkevich","year":"2012","unstructured":"Abkevich, V. et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107, 1776\u20131782 (2012).","journal-title":"Br. J. Cancer"},{"key":"406_CR40","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41375-018-0017-0","volume":"32","author":"C Pawlyn","year":"2018","unstructured":"Pawlyn, C. et al. Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition? Leukemia 32, 1561\u20131566 (2018).","journal-title":"Leukemia"},{"key":"406_CR41","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli, M. L. et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin. Cancer Res. 22, 3764\u20133773 (2016).","journal-title":"Clin. Cancer Res."},{"key":"406_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"406_CR43","unstructured":"MedDRA. Medical Dictionary for Regulatory Activities Version 21.0, https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/dist_file_format_21_0_english.pdf (2018)."},{"key":"406_CR44","unstructured":"NCI. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf (2009)."},{"key":"406_CR45","doi-asserted-by":"crossref","unstructured":"McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).","DOI":"10.1186\/s13059-016-0974-4"},{"key":"406_CR46","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper, C. J. & Pearson, E. S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26, 404\u2013413 (1934).","journal-title":"Biometrika"},{"key":"406_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer, R. & Crowley, J. A confidence interval for the median survival time. Biometrics 38, 29\u201341 (1982).","journal-title":"Biometrics"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00406-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00406-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00406-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:24:52Z","timestamp":1669299892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00406-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["406"],"URL":"https:\/\/doi.org\/10.1038\/s41523-022-00406-0","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"assertion":[{"value":"2 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L.T.: advisory role: AbbVie, Aduro, Blueprint Medicines Celgene, Daiichi Sankyo, Genentech, G1 Therapeutics, Immunomedics, Lilly, Merck & Co., Natera, OncoSec Medical, Pfizer. Institutional research funding from AbbVie, AstraZeneca, Bayer, Biothera, Calithera, EMD Serono, Billerica, MA USA, Genentech, Merck & Co., OncoSec Medical, Pfizer, PharmaMar, Tesaro, Vertex. S.M.T.: Institutional research funding from AstraZeneca, Lilly, Merck & Co., Nektar, Novartis, Pfizer, Genentech\/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, and Seattle Genetics; has served as an advisor\/consultant to AstraZeneca, Lilly, Merck & Co., Nektar, Novartis, Pfizer, Genentech\/Roche, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Puma, Silverback Therapeutics, G1 Therapeutics, AbbVie, Anthenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, Gilead, and Samsung Bioepsis Inc. G.I.S. has received research funding from Eli Lilly, the healthcare business of EMD Serono, Billerica, MA USA, Merck & Co., and Sierra Oncology. He has served on advisory boards for Pfizer, Eli Lilly, G1 Therapeutics, Roche, the healthcare business of EMD Serono, Billerica, MA USA, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Seattle Genetics, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin, Concarlo Holdings, Syros, Zentalis and CytomX Therapeutics. In addition, he holds a patent entitled, \u201cDosage regimen for sapacitabine and seliciclib,\u201d also issued to Cyclacel Pharmaceuticals, and a pending patent, entitled, \u201cCompositions and Methods for Predicting Response and Resistance to CDK4\/6 Inhibition,\u201d together with Liam Cornell. M.M.: personal fees from Amgen, grants and personal fees from Roche, grants from AstraZeneca, grants and personal fees from GSK, personal fees and other from Novartis, other from Millenium, personal fees, non-financial support and other from Immunocore, personal fees and other from BMS and Eisai, other from Pfizer, personal fees, non-financial support and other from MSD, personal fees and other from Rigontec (acquired by MSD), other from Regeneron, personal fees from BiolineRx, personal fees and other from Array Biopharma (now Pfizer), non-financial support and other from Replimune, personal fees from Kineta, and personal fees from Silicon Therapeutics, outside the submitted work. S.R.L.: personal fees from Eisai, Shionogi and Prosigna, and was previously employed by Pfizer, research funding from Pathios Therapeutics, received travel, accommodation or expenses from Pfizer, Roche, Synthon and Piqur Therapeutics, cofounder and stock holding in Mitox Therapeutics. H.-T.A. has served as an advisor\/consultant for Bicycle Therapeutics, Biontech, Bayer, Beigene, Servier, Roche and Guardant Health, and honoraria from Bicycle Therapeutics, Biontech, Bayer, Beigene, Servier, Roche and Guardant Health. A.T.: AstraZeneca-Financial support to academic and hospital institutions for costs associated with academic study chair and local site costs for OlympiA trial\/Travel expenses related to any trial related travel\/Payments to Institution through Breast International Group for trial conduct in Olympia trial and through CRO\u2019s for commercial PARP inhibitor trials AstraZeneca with royalties paid by Institute of Cancer Research with royalties paid for use of PARP inhibitors in DNA deficient cancers, licensee - AstraZeneca. Payments to Institute of Cancer Research and personally through ICR rewards to Inventors scheme. the healthcare business of Merck KGaA, Darmstadt, Germany: local site trial support costs associated with clinical trial. Pfizer: personal fees\/Advisory Board related to targeted therapies in DNA repair deficient cancers. Vertex: personal fees from\/Advisory Board related to targeted therapies in DNA repair deficient. Artios: personal fees\/Advisory Board related to targeted therapies in DNA repair deficient cancers. Prime Oncology-Personal fees\/Advisory Board related to targeted therapies in DNA repair deficient cancers. Medivation: financial support for research at ICR. Breast Cancer Now Charity: grant funded to study homologous recombination deficient breast and other cancers, BCN receive payments through AstraZeneca related to PARP inhibitor patents. CRUK: grant funded to study homologous recombination deficient breast and other cancers, CRUK receive payments through AstraZeneca related to PARP inhibitor patents\/personal fees\/honoraria associated with function as Deputy Chair and reviewer for CRUK Clinical Research committee. Inbiomotion: personal fees\/Scientific Ad Board function and stock options. MD Anderson: personal fees\/Moon shot Breast Cancer scientific advisory board honoraria. Medscape Education honorarium from Merck & Co. educational grant: personal fees\/speaker for a video series. V.A. has received consulting fees from Daiichi Sankyo and Eisai and research grants from Genentech. E.D. was an employee and stockholder at AstraZeneca subsequent to involvement in this study. T.C.H. has received research funding from Takeda Oncology. R.W. has received research funding from Acerta Pharma and AstraZeneca; served on advisory boards for Puma Biotechnology, Pfizer; and served on speakers\u2019 bureau for Roche Diagnostics. J.F.-P. is an employee of Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. T.Go. and T.Gr. are employees of the healthcare business of Merck KGaA, Darmstadt, Germany. J.D. is an employee of EMD Serono, Billerica MA, USA. P.F.-M.: an employee of EMD Serono, Billerica MA, USA. I.D.-P. was an employee of Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, at the time of the study and is currently an employee of GlaxoSmithKline, Zug, Switzerland. R.P. has received honoraria for attending advisory boards from Pierre Faber, Bayer, Octimet, Clovis Oncology, Novartis, Karus Therapeutics, Biosceptre, BMS, Cybrexa, Ellipses, CV6 Therapeutics, Astex Therapeutics and Sanofi Aventis. Fees for delivery of educational talks or chairing educational meetings by AstraZeneca, Novartis, Bayer, Tesaro and BMS. Funds to support attendance at conferences from BMS and MSD.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}